Format

Send to

Choose Destination
Int J Neurosci. 2019 Feb;129(2):119-128. doi: 10.1080/00207454.2018.1481066. Epub 2018 Sep 13.

Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.

Author information

1
a Neurology Department , Thomayer's Hospital , Praha , Czechia.
2
b O. Meany Consultancy GmbH , Hamburg , Germany.
3
c Market Access Manager , Almirall Hermal GmbH , Reinbek , Germany.
4
d Clinical Statistics , Almirall S.A. , Barcelona , Spain.
5
e International Clinical Trial Managers , Almirall Hermal GmbH , Reinbek , Germany.
6
f Neurology Medical Manager , Global Medical Affairs, Almirall S.A. , Barcelona , Spain.

Abstract

Purpose/aim: To evaluate the efficacy of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex®) as add-on therapy to optimised standard antispasticity treatment in patients with moderate to severe multiple sclerosis (MS) spasticity.

METHODS:

Sativex® as add-on therapy vs. further optimised first-line ANTispastics (SAVANT) was a two-phase trial. In Phase A, eligible patients received add-on THC:CBD spray for 4 weeks to identify initial responders [≥20% improvement from baseline in spasticity 0-10 numerical rating scale (NRS) score]. Following washout, eligible initial responders were randomised to receive THC:CBD spray or placebo for 12 weeks (double-blinded, Phase B). Optimisation of underlying antispasticity medications was permitted in both groups across all study periods.

RESULTS:

Of 191 patients who entered Phase A, 106 were randomised in Phase B to receive add-on THC:CBD spray (n = 53) or placebo (n = 53). The proportion of clinically relevant responders after 12 weeks (≥30% NRS improvement; primary efficacy endpoint) was significantly greater with THC:CBD spray than placebo (77.4 vs. 32.1%; p < 0.0001). Compared with placebo, THC:CBD spray also significantly improved key secondary endpoints: changes in mean spasticity NRS (p < 0.0001), mean pain NRS (p = 0.0013), and mean modified Ashworth's scale (p = 0.0007) scores from Phase B baseline to week 12. Adverse events, when present, were mild/moderate and without new safety concerns.

CONCLUSIONS:

Add-on THC:CBD oromucosal spray provided better and clinically relevant improvement of resistant MS spasticity compared with adjusting first-line antispasticity medication alone.

KEYWORDS:

Multiple sclerosis; Sativex; THC:CBD; nabiximols ; spasticity

PMID:
29792372
DOI:
10.1080/00207454.2018.1481066
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center